We have reported previously that a canalicular multispecific organic anion transporter
(cMOAT) is responsible for the biliary excretion of carboxylate forms of irinotecan, 7-ethyl-10 …

Pharmacokinetic modulation of irinotecan (CPT-11) with cyclosporine (INN, ciclosporin) and
phenobarbital has been reported in the Journal. 1 CPT-11 is widely used in the treatment of …

PURPOSE: To determine experimentally the intestinal permeability of the anticancer
prodrug irinotecan, and to quantify the amount of its cytotoxic metabolite SN-38 that is …

Abstract Purpose Irinotecan (CPT-11) is a camptothecin derivative whose potent anti-tumor
activity depends on the rapid formation of an in vivo active metabolite, SN38 (7-ethyl-10 …

Irinotecan (CPT-11, 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin) has
exhibited clinical activities against a broad spectrum of carcinomas by inhibiting DNA …

The pharmacokinetics of CPT-11 administered into rats to evaluate the future possibility of ip
administration was investigated. Serum, bile juice, and intraperitoneal fluid was collected to …

Biotransformation of irinotecan (CPT-11) into its pharmacologic active metabolite SN-38 was
investigated in patients treated for advanced colorectal cancer. A dose of 180 mg/m2 CPT …

Abstract Irinotecan (CPT‐11) is a semisynthetic derivative of camptothecine that has proved
activity in the treatment of colorectal carcinoma. The metabolites identified in humans …

Aim: To investigate the effect of breast cancer resistance protein (BCRP) inhibitors and
pharmaceutical excipients on reducing the biliary excretion of camptothecins (CPT) …

Ethyl-10-hydroxycamptothecin (SN-38) is the active metabolite of an anticancer drug,
irinotecan (CPT-11). Severe late diarrhea is the dose-limiting toxic effect of CPT-11. This …